参考资料:[1] X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome. Retrieved April 29, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html[2] Current Corporate Presentation. Retrieved October 31, 2023 from https://investors.x4pharma.com/static-files/eae36b57-f69f-4fba-ad24-eb1012be88b2